The Role of Oral Therapies in Plaque Psoriasis Treatment

Panelists discuss how oral therapies have become an increasingly important part of the psoriasis treatment landscape, particularly for patients with moderate to severe plaque psoriasis. They note that while biologics remain a gold standard for efficacy, oral options provide flexibility and appeal for patients who prefer noninjectable alternatives. The discussion emphasizes how treatment selection should reflect both disease severity and patient lifestyle factors.

Panelists discuss how oral agents such as deucravacitinib and apremilast can bridge the gap between topicals and biologics, addressing barriers such as cost, convenience, and fear of needles. They highlight that clinicians now have a wider spectrum of choices that allow for stepwise treatment strategies. This expanding range supports shared decision-making and personalization of care.

Panelists discuss how patient preference and adherence play central roles in therapeutic success. They agree that patient education on expectations and dosing can increase satisfaction and long-term outcomes, reinforcing the value of oral therapies as viable first- or second-line treatments in appropriately selected patients.